C5AR

AcronymDefinition
C5ARC5a Receptor
References in periodicals archive ?
The report includes a compilation of current active projects in research and development of C5a and C5aR antagonists.
Corporate C5a & C5aR Antagonist R&D Pipelines
Data Establish ChemoCentryx Drug as the First True Orally-Active Small Molecule C5aR Inhibitor
Phase 1 Clinical Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Novel C5aR antagonist CCX168, a Potential Therapeutic for ANCA-Vasculitis"
We are very pleased to report that CCX168 appears to be the first true orally-active small molecule C5aR antagonist drug ever advanced into the clinic," stated Thomas J.
Pharmacokinetic and pharmacodynamic data indicated that 30 to 50 mg of CCX168 given orally twice daily in humans results in greater than 90% C5aR coverage in blood at all times, and this is considered optimal for CCX168 evaluation in Phase II trials in vasculitis.
In this study, human C5aR transgenic mice were employed, and ANCA kidney disease was profoundly inhibited by doses of CCX168 that are very similar to those achieved safely in the human Phase I studies.
Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development.
Additional clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus, CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis and CCX168, a C5aR antagonist, in Phase I clinical development.